Ludwigshafen, Germany (ots/PRNewswire) - - BASF proposes nominees for a majority of the Engelhard Board of Directors BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that, through its wholly owned subsidiary, Iron Acquisition Corporation, it has extended the expiration date of its tender offer with the Securities ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF's All-Cash Bid Provides Greater Value and Certainty than Engelhard's Proposal BASF is considering all its options after Engelhard's Board of Directors rejected an increased cash offer of US$38 per share proposed by BASF, as part of a negotiated merger transaction, and elected instead to pursue a partial share buyback plan. Following a preliminary review of Engelhard's proposed transaction, BASF continues to ...
Ludwigshafen, Germany (ots/PRNewswire) - BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced that, through its wholly owned subsidiary, Iron Acquisition Corporation, it has extended the expiration date of its US$37 cash tender offer for all of the issued and outstanding shares of common stock of Engelhard Corporation (NYSE: EC) to 5:00 p.m., New York City time, on Friday, ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
Ludwigshafen, Germany (ots) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, today announced that it is commencing a cash tender offer for all of the outstanding shares of common stock of Engelhard Corporation (NYSE: EC) for US$37.00 net per share. BASF's price represents a 23% premium above the December 20, 2005 closing price of Engelhard's ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Ludwigshafen (ots) - - Further strong increase in sales and EBIT before special items - Sales prices increased to reflect higher raw materials costs - Risks due to high raw materials prices - Outlook for full year 2004: - Significant increase in sales and EBIT before special items - Premium will be earned on cost of capital BASF continued on its successful course in the third quarter of 2004 and again posted excellent ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Ludwigshafen, Germany (ots) - - Volume growth in all segments - Chemicals activities improve significantly - Cash flow increases further - High raw materials have negative impact - Outlook for full year 2004: Higher EBIT before special items expected BASF again showed that it can maintain a good course, even in stormy economic weather. "We perform consistently thanks to our ...
Ludwigshafen (ots) - - Sales rise substantially in 2003 despite negative currency effects - EBIT before special items higher than in previous year - Fourth quarter substantially better than expected - Cash flow at record level - Agricultural Products & Nutrition increases sales and earnings BASF's figures for 2003 clearly show that the tremendous hard work by the company's ...
Freudenberg & Co. Kommanditgesellschaft
Weinheim/Munich (ots) - Klüber remains key company / Chem-Trend rounds off portfolio Freudenberg & Co., Weinheim, Germany, has acquired the US release agents company Chem-Trend, of Howell, Michigan. The takeover reinforces the specialities operations of the diversified industrial Group. In order to consolidate the lubrication activities Freudenberg has formed the new business group, "Freudenberg ...
Ludwigshafen, Germany (ots) - Difficult third quarter - BASF proceeds with its restructuring Measures - Sales increase slightly despite negative currency effects - EBIT before special items below the previous year's good level - Significant improvement in Agricultural Products & Nutrition - Oil & Gas makes largest contribution to income - ...
Ludwigshafen, Germany (ots) - - Good performance in the second quarter of 2003: EBIT before special items up slightly on 2002 - Agricultural Products & Nutrition segment improves significantly - Additional restructuring program to strengthen profitability in the NAFTA region - Full year 2003: major efforts needed to match last year's earnings BASF is continuing to perform well in a ...
Ludwigshafen, Germany (ots) - Good start to 2003 - cautious outlook - Sales climb due to significant increase in volumes and a high oil price - Income from operations before special items up 15 percent - Second-quarter sales and earnings expected to increase only slightly compared with previous year BASF has made a good start to 2003. "Our numbers show yet again that with ...
The original document "Key figures from our 2002 Financial Report" is available for download in the digital press kit at: http://www.presseportal.de/galerie.htx?type=dok Ludwigshafen (ots) - BASF significantly increases earnings - Position as leading chemical company maintained - EBIT before special items climbs by more than 25 percent - Turnaround in NAFTA - strong upturn in Asia - ...
Ludwigshafen (ots) - On Tuesday, March 18, 2003, the Annual Press Conference of BASF Aktiengesellschaft will be held in Ludwigshafen. At this time the company will present the results of the year 2002. The following information about this conference can be found on this date on the Internet at: · Financial Report 2002 German: www.basf.de/finanzbericht from 07.30 a.m. CET English: ...
Ludwigshafen, Germany (ots) - - Cross-reference: BASF-Fall Press Conference on November 13, 2001 is available free of chargeas Original Video Service (ovs) at http://www.presseportal.de/galerie.htx?type=ovs We will publish BASF's Third Quarter Interim Report on the occasion of the Fall Press Conference on November 13, 2001, in Ludwigshafen. You will receive it at 7:30 a.m. (CET). On November 13, 2001 you can also obtain further information from the Internet ...
Ludwigshafen (ots) - * All segments post positive earnings * Product prices and margins under pressure * Higher earnings in Oil & Gas * Earnings in 2001 likely to be lower than in 2000 * Share buy-back program to be accelerated BASF has continued to weather difficult economic conditions. All of BASF's segments posted positive earnings before special items in the second quarter of 2001. The ...
